227 related articles for article (PubMed ID: 37592287)
21. A site specific model and analysis of the neutral somatic mutation rate in whole-genome cancer data.
Bertl J; Guo Q; Juul M; Besenbacher S; Nielsen MM; Hornshøj H; Pedersen JS; Hobolth A
BMC Bioinformatics; 2018 Apr; 19(1):147. PubMed ID: 29673314
[TBL] [Abstract][Full Text] [Related]
22. decompTumor2Sig: identification of mutational signatures active in individual tumors.
Krüger S; Piro RM
BMC Bioinformatics; 2019 Apr; 20(Suppl 4):152. PubMed ID: 30999866
[TBL] [Abstract][Full Text] [Related]
23. Hotspots of Human Mutation.
Nesta AV; Tafur D; Beck CR
Trends Genet; 2021 Aug; 37(8):717-729. PubMed ID: 33199048
[TBL] [Abstract][Full Text] [Related]
24. Patterns and processes of somatic mutations in nine major cancers.
Jia P; Pao W; Zhao Z
BMC Med Genomics; 2014 Feb; 7():11. PubMed ID: 24552141
[TBL] [Abstract][Full Text] [Related]
25. The shaping of cancer genomes with the regional impact of mutation processes.
Lee SY; Wang H; Cho HJ; Xi R; Kim TM
Exp Mol Med; 2022 Jul; 54(7):1049-1060. PubMed ID: 35902761
[TBL] [Abstract][Full Text] [Related]
26. An overview of mutational and copy number signatures in human cancer.
Steele CD; Pillay N; Alexandrov LB
J Pathol; 2022 Jul; 257(4):454-465. PubMed ID: 35420163
[TBL] [Abstract][Full Text] [Related]
27. Characteristics of mutational signatures of unknown etiology.
Hu X; Xu Z; De S
NAR Cancer; 2020 Sep; 2(3):zcaa026. PubMed ID: 33015626
[TBL] [Abstract][Full Text] [Related]
28. The topography of mutational processes in breast cancer genomes.
Morganella S; Alexandrov LB; Glodzik D; Zou X; Davies H; Staaf J; Sieuwerts AM; Brinkman AB; Martin S; Ramakrishna M; Butler A; Kim HY; Borg Å; Sotiriou C; Futreal PA; Campbell PJ; Span PN; Van Laere S; Lakhani SR; Eyfjord JE; Thompson AM; Stunnenberg HG; van de Vijver MJ; Martens JW; Børresen-Dale AL; Richardson AL; Kong G; Thomas G; Sale J; Rada C; Stratton MR; Birney E; Nik-Zainal S
Nat Commun; 2016 May; 7():11383. PubMed ID: 27136393
[TBL] [Abstract][Full Text] [Related]
29. Mutation hotspots at CTCF binding sites coupled to chromosomal instability in gastrointestinal cancers.
Guo YA; Chang MM; Huang W; Ooi WF; Xing M; Tan P; Skanderup AJ
Nat Commun; 2018 Apr; 9(1):1520. PubMed ID: 29670109
[TBL] [Abstract][Full Text] [Related]
30. Recurrent promoter mutations in melanoma are defined by an extended context-specific mutational signature.
Fredriksson NJ; Elliott K; Filges S; Van den Eynden J; Ståhlberg A; Larsson E
PLoS Genet; 2017 May; 13(5):e1006773. PubMed ID: 28489852
[TBL] [Abstract][Full Text] [Related]
31. SigsPack, a package for cancer mutational signatures.
Schumann F; Blanc E; Messerschmidt C; Blankenstein T; Busse A; Beule D
BMC Bioinformatics; 2019 Sep; 20(1):450. PubMed ID: 31477009
[TBL] [Abstract][Full Text] [Related]
32. Mutational signatures of redox stress in yeast single-strand DNA and of aging in human mitochondrial DNA share a common feature.
Degtyareva NP; Saini N; Sterling JF; Placentra VC; Klimczak LJ; Gordenin DA; Doetsch PW
PLoS Biol; 2019 May; 17(5):e3000263. PubMed ID: 31067233
[TBL] [Abstract][Full Text] [Related]
33. Hidden Markov models lead to higher resolution maps of mutation signature activity in cancer.
Wojtowicz D; Sason I; Huang X; Kim YA; Leiserson MDM; Przytycka TM; Sharan R
Genome Med; 2019 Jul; 11(1):49. PubMed ID: 31349863
[TBL] [Abstract][Full Text] [Related]
34. The landscape and driver potential of site-specific hotspots across cancer genomes.
Juul RI; Nielsen MM; Juul M; Feuerbach L; Pedersen JS
NPJ Genom Med; 2021 May; 6(1):33. PubMed ID: 33986299
[TBL] [Abstract][Full Text] [Related]
35. Signatures of mutational processes in human cancer.
Alexandrov LB; Nik-Zainal S; Wedge DC; Aparicio SA; Behjati S; Biankin AV; Bignell GR; Bolli N; Borg A; Børresen-Dale AL; Boyault S; Burkhardt B; Butler AP; Caldas C; Davies HR; Desmedt C; Eils R; Eyfjörd JE; Foekens JA; Greaves M; Hosoda F; Hutter B; Ilicic T; Imbeaud S; Imielinski M; Jäger N; Jones DT; Jones D; Knappskog S; Kool M; Lakhani SR; López-Otín C; Martin S; Munshi NC; Nakamura H; Northcott PA; Pajic M; Papaemmanuil E; Paradiso A; Pearson JV; Puente XS; Raine K; Ramakrishna M; Richardson AL; Richter J; Rosenstiel P; Schlesner M; Schumacher TN; Span PN; Teague JW; Totoki Y; Tutt AN; Valdés-Mas R; van Buuren MM; van 't Veer L; Vincent-Salomon A; Waddell N; Yates LR; ; ; ; ; Zucman-Rossi J; Futreal PA; McDermott U; Lichter P; Meyerson M; Grimmond SM; Siebert R; Campo E; Shibata T; Pfister SM; Campbell PJ; Stratton MR
Nature; 2013 Aug; 500(7463):415-21. PubMed ID: 23945592
[TBL] [Abstract][Full Text] [Related]
36. Experimental systems for the analysis of mutational signatures: no 'one-size-fits-all' solution.
Ivanov D; Hwang T; Sitko LK; Lee S; Gartner A
Biochem Soc Trans; 2023 Jun; 51(3):1307-1317. PubMed ID: 37283472
[TBL] [Abstract][Full Text] [Related]
37. Mutational signature SBS8 predominantly arises due to late replication errors in cancer.
Singh VK; Rastogi A; Hu X; Wang Y; De S
Commun Biol; 2020 Aug; 3(1):421. PubMed ID: 32747711
[TBL] [Abstract][Full Text] [Related]
38. Theoretical analysis of mutation hotspots and their DNA sequence context specificity.
Rogozin IB; Pavlov YI
Mutat Res; 2003 Sep; 544(1):65-85. PubMed ID: 12888108
[TBL] [Abstract][Full Text] [Related]
39. Divergent mutational processes distinguish hypoxic and normoxic tumours.
Bhandari V; Li CH; Bristow RG; Boutros PC;
Nat Commun; 2020 Feb; 11(1):737. PubMed ID: 32024819
[TBL] [Abstract][Full Text] [Related]
40. FIREVAT: finding reliable variants without artifacts in human cancer samples using etiologically relevant mutational signatures.
Kim H; Lee AJ; Lee J; Chun H; Ju YS; Hong D
Genome Med; 2019 Dec; 11(1):81. PubMed ID: 31847917
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
